ADCT

ADC Therapeutics SA

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1.41

Price (1 Year)

$4.3 $1

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %143.6 / %30
Non-compliant assets / Total market cap %0 / %30
Non-compliant revenue / Total income %8.1 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.

Website

Analysis (Turkish): ADCT Hissesi Caiz mi, Helal mi? ADC Therapeutics SA Katılım Analizi